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Cancer of unknown primary (CUP) is a clinical syndrome representing many types of cancers 
and diagnoses are typically made after review of clinical presentation, pathology (including 
immunohistochemical staining) and imaging studies. Treatment with systemic chemotherapy 
has been shown to result in fairly reproducible objective response rates. Herein, a case of a 
patient who was initially diagnosed with a poorly differentiated adenocarcinoma of 
unknown origin is reported. After mRNA gene expression profiling (commercially available 
CancerTYPE ID), a specific diagnosis of papillary renal cell carcinoma (RCC) was made and 
then confirmed with additional immunohistochemical staining. The patient was treated with 
targeted therapy and an objective radiographic response was seen. A literature review 
suggests this to be the first patient with papillary RCC, identified by molecular profiling, and 
benefitting from a targeted agent that otherwise would not have been considered in the 
setting of CUP. This case underscores the importance of considering the use of newer testing 
technologies in the interest of offering patients more specific, targeted therapy in order to 
improve efficacy and spare patients toxicities of less specific, empiric chemotherapeutic 
regimens. 
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Various guidelines have been suggested for appropriate evaluation of metastatic 
cancers when the primary tumor site is not readily identifiable based on the clinical 
presentation, tissue histology and immunohistochemical staining. After such 
evaluation, cancer of unknown primary (CUP) is the diagnosis made in about 4–5% of 
invasive cancers [1]. Series of patients with this diagnosis have been studied and 
treated with empiric combination chemotherapy regimens. Both the specific 
recommended regimens and the efficacy of these therapies vary by the histologic 
subtype and immunohistochemical and clinical presentation [2]. Objective response 
rates in the range of 30–50% have been described in many published series [3]. For 
example, in a series of 71 patients treated with paclitaxel, carboplatin and oral 
etoposide, 46% of patients had a major objective response with a median survival of 11 
months [4]. 
The National Comprehensive Cancer Network (NCCN) has published guidelines with 
recommendations concerning evaluation and care for patients with CUP [2]. Molecular 
profiling is described as an ‘emerging diagnostic tool’, with the potential of identifying 
the likely primary based on comparison of expression patterns in the unknown tumor 
relative to known data banks that include known primaries [5–10]. Confirming the 
specificity of the testing in a particular patient remains challenging, if not impossible, 
short of autopsy series; however, with improved chemotherapy and targeted therapies 
now available for several solid tumors, a more site-specific therapy is likely to be 
superior for CUP patients diagnosed with a specific tissue of origin compared to the 
administration of an empiric broad-spectrum chemotherapy regimen. Ultimately, the 
recognition of specific molecular abnormalities (mutations) in tumor cells which can be 
targeted with specific drugs is likely to be far more clinically relevant than even 
identifying the primary tissue of origin in terms of choosing therapies. Herein, we 
describe a patient initially diagnosed with CUP. Expression profiling strongly suggested 
the tissue of origin to be the kidney and the patient’s tumor responded well and 
durably to a targeted agent which is FDA approved for treating metastatic kidney 
cancer. 
Case Report 
PG is a 53-year-old male who presented in April 2011 with right hip pain. Plain films revealed 
osteoarthritis and physical examination showed left neck lymphadenopathy. CT, PET/CT and MRI 
scanning confirmed diffuse lymphadenopathy with the PET scan showing markedly increased FDG 
uptake involving the left neck and supraclavicular regions (left supraclavicular lymph node measuring 
4.1 × 2.6 cm), mediastinal, retroperitoneal, bilateral and common external and internal iliac lymph 
node chains. The MRI report noted ‘extensive retroperitoneal’ and ‘retrocrural adenopathy’ as well as 
a large necrotic mass apparently ‘invading’ the right kidney, and an adrenal gland felt also to 
represent ‘metastatic nodes’. Left supraclavicular lymph node biopsy showed a ‘poorly differentiated 
adenocarcinoma’. Immunohistochemical staining was done including negative staining for cytokeratin 
20, TTF-1, calretinin, CA19-9, WT-1 and D2-40, and strongly positive staining for cytokeratin 7. The 
phenotype was felt to be consistent with a pancreatobiliary, lung or upper GI primary site. 
The pathologists wrote ‘the morphology does not suggest a renal or adrenal primary’, a question 
that had been raised based on the scans above. CEA, HCG and AFP were normal, while CA19-9 was 
64.9 units/ml (normal range 0–35) and LDH was 214 IU/l (98–192).  
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The tumor was sent for mRNA expression profiling [11] (bioTheranostics, San Diego, Calif., USA) 
and the report suggested a 95% ‘probability’ of this cancer representing kidney cancer with a 94% 
‘probability’ of the tumor being a papillary renal cell carcinoma (RCC). Because of the bioTheranostics 
expression profiling result, further immunostaining was done. The tumor stained strongly positive for 
racemace (AMACR), RCC antigen and CD10. The pathologist concluded that ‘the immunohistochemical 
profile strongly supports the tumor to be renal in origin and specifically papillary renal carcinoma’. 
The patient was treated with everolimus (10 mg po qd) beginning on May 10, 2011, and, 2 weeks 
later, reported a diminution in the supraclavicular fullness. On June 23, 2011, a pelvic MRI was 
repeated and the report noted a mild decrease in the size of the retroperitoneal adenopathy. On July 5, 
2011, a PET/CT was interpreted as showing relatively decreased FDG uptake in multiple lymph node 
regions ‘suggestive of some interval treatment response’ since the prior PET/CT. In March 2012, 
scans continued to show no evidence of progression of his malignancy. 
Discussion 
With improved chemotherapy and targeted therapies now available for several solid 
tumors, a more site-specific therapy is likely to be superior for CUP patients diagnosed 
with a specific tissue of origin compared to the administration of an empiric broad-
spectrum chemotherapy regimen. In the case described above, kidney cancer was 
identified as the likely cancer type through expression profiling, and the patient was 
successfully treated with a targeted agent indicated for treatment of that cancer type. 
Treating some CUP patients with systemic therapies described for known 
counterpart primaries based on gene expression profiling has resulted in more 
favorable outcomes compared to those outcomes reported for historic controls of CUP 
patients treated with the less specific regimens, where no expression profiling was 
completed. For example, Greco et al. [12] recently noted a 64% RR and a 22-month 
median survival for 32 CUP patients identified by expression profiling as having 
probable colorectal primaries (although colonoscopies were negative in 30 of the 32 
patients), while historic controls with CUP treated with CUP regimens, rather than 
colorectal regimens, had a 9-month median survival. Still, no prospective randomized 
studies have been done and, in spite of small series such as the one above, it may be 
that while a molecular profile can be consistent with that of a particular primary, the 
response to available therapies may be different for these tumors, since the biological 
behavior of CUP may be different from their more readily identifiable counterparts. The 
NCCN panel concluded ‘the panel does not recommend molecular profiling as part of 
routine evaluation’ and suggests no specific circumstances in which such testing should 
be considered. 
Conclusions 
After reviewing the literature, this case appears to represent the first case of a 
papillary renal carcinoma where expression profiling was used to identify the primary, 
more specific immunostaining was used to confirm the diagnosis, and the patient was 
treated with a targeted agent, which resulted in a response. Everolimus is an FDA 
approved targeted agent for the treatment of advanced renal carcinoma based on a 
study showing that, compared to placebo, everolimus more than doubled the time 
without tumor growth or death [13]. Such therapy clearly would not have been a 
consideration if not for the pursuit of the molecular profiling. Our patient’s tumor  
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initially responded to everolimus and has shown no progression for over 10 months. 
While choosing which specific patients will benefit from expression profiling remains 
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